Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35
Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.
Novo Norodisk caps insulin prices at $35 for Minnesotans
Now Novo Nordisk is required to provide insulin products at $35 per monthly prescription for customers paying with cash. The settlement also requires all three companies to use a texting system to raise awareness of low-cost insulin options, according to the press release.
When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
11don MSN
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it ...
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...
Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback